Biological Dynamics Appoints Paul Billings, MD, PhD to Board of Directors
/SAN DIEGO, CA—Biological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE) - based diagnostics, announces the appointment of Paul Richard Billings, MD, PhD, FACP, FACMG to the Company’s Board of Directors. His addition increases Board membership to four directors.
Dr. Billings is a nationally recognized expert in genomics and molecular medicine. He is renowned for his contribution to improving patient care by bringing in new genomic technologies to the clinic. He currently serves as an Executive-in-Residence at Janssen Diagnostics, a division of Johnson & Johnson Inc., and is the Medical Director of the IMPACT Cancer Care Program at Thermo Fisher Scientific (TFS).
Dr. Billings brings to Biological Dynamics a blend of business, research, regulatory, and health care experiences. Dr. Billings has served on the Scientific Advisory Board of the FDA and the Genomic Medicine Advisory Committee at the Department of Veterans Affairs. He has also held academic appointments at Harvard University, U.C. San Francisco, Stanford University, and U.C. Berkeley, and has served as a physician at a number of leading medical centers.
Dr. Billings’ business background ranges from guiding clinical strategies as a Chief Medical Officer of Life Technologies Inc.- and then of the Genetic Sciences Division of Thermo Fisher Scientific - to fostering the success of several early stage genetic and diagnostic companies. Dr. Billings has founded and led GeneSage Inc., Omicia Inc., and CELLective Dx Corporation. He is currently a Board Director of Trovagene Inc. and Renova Health Inc., both publicly traded personalized medicine companies.
“Biological Dynamics is bringing to market a technology that could potentially revolutionize how we look at individual response to cancer treatments,” said Dr. Billings. “Treatment response is at the crux of precision medicine. It is a key input into treatment plans; adding clarity to evaluating individual responses will drive better plans, and ultimately, better patient outcomes.”
“We are fortunate to have Dr. Billings bring his extensive expertise in bringing promising technologies to clinical markets to our Board,” says Raj Krishnan, CEO of Biological Dynamics - “With the new funding fueling our regulatory and commercialization efforts for our first oncology product, TR(ACE)™, Dr. Billings’ guidance in navigating the ecosystem of patient care will be essential to our success.”
About Biological Dynamics
Biological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions. Blood based nanoparticles have been shown to be clinically relevant in a number of therapeutic areas, including oncology, transplant health, and reproductive medicine.
The company’s first product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. Food and Drug Administration or any foreign regulatory agency.
